Obesity Drug

Wall Street Closes Out Strong Quarter as Investors Weigh Lilly's Mixed Obesity Drug Data

Stocks wrapped up a strong quarter even as new trial data on Eli Lilly's obesity treatment delivered a mixed picture for investors.